# Dual Vaccine Trial in Myeloproliferative Neoplasms

> **NCT04051307** · PHASE1,PHASE2 · COMPLETED · sponsor: **Inge Marie Svane** · enrollment: 9 (actual)

## Conditions studied

- Polycythemia Vera
- Essential Thrombocythemia

## Interventions

- **DRUG:** PD-L1 peptide: PD-L1 Long(19-27) Peptide sequence: FMTYWHLLNAFTVTVPKDL
- **DRUG:** Arginase1 peptide: ArgLong2(169-206) Peptide sequence ISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRL

## Key facts

- **NCT ID:** NCT04051307
- **Lead sponsor:** Inge Marie Svane
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-10
- **Primary completion:** 2022-07-10
- **Final completion:** 2022-07-10
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2023-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04051307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04051307, "Dual Vaccine Trial in Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04051307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*